Child’s Suspected Brain Tumour Turned Out to Be Accidental Vitamin D Overdose
When a young boy began exhibiting severe headaches, visual disturbances, and episodes of nausea that prompted his parents to fear the worst possible diagnosis—a brain tumour—the ensuing medical investigations, instead of confirming a malignant growth, ultimately uncovered an entirely different cause rooted in an accidental overdose of a supplement intended to alleviate growing pains.
The initial clinical assessment conducted by the family’s primary care physician, prompted by the child’s rapidly deteriorating condition, involved a series of neuroimaging studies, blood tests, and specialist referrals, all of which, while thorough, failed to reveal any intracranial mass yet did highlight abnormal biochemical markers consistent with hypervitaminosis, thereby shifting the diagnostic focus from an oncological to a metabolic pathology.
Subsequent review of the child’s medication history, a process undertaken by the consulting pediatric endocrinologist who was called in to interpret the biochemical anomalies, identified that a high-dose vitamin D preparation—prescribed a few weeks earlier to address presumed deficiencies associated with the child’s reported growing pains—had been administered at a quantity exceeding the recommended therapeutic range, a dosage error that, according to the prescribing physician’s own admission, stemmed from a misinterpretation of the product’s concentration and a failure to cross‑check the child’s weight‑based dosing calculations.
While the prescribing physician’s oversight illustrates a broader systemic vulnerability in ensuring safe paediatric dosing, especially for micronutrients that are often perceived as benign, the incident also exposes a gap in pharmacy verification processes, since the dispensed product, although correctly labelled, was not subjected to a double‑check protocol that might have caught the discrepancy between prescribed and actual daily intake before the medication reached the household.
In the aftermath of the discovery, the child’s symptoms—most notably the headache and visual disturbances that had initially alarmed his parents—were attributed to the neurotoxic effects of excessive vitamin D, a condition that, although rare, is well documented in medical literature and is known to cause hypercalcaemia, intracranial pressure fluctuations, and associated neurological manifestations that can masquerade as neoplastic processes.
The corrective measures implemented included immediate cessation of the vitamin D supplement, initiation of a monitored hydration regimen designed to promote calciuric excretion, and close observation by the paediatric team to ensure that serum calcium levels returned to within normal limits, a therapeutic pathway that, based on the child’s response over the subsequent days, resulted in a rapid alleviation of the previously reported symptoms and a full recovery without lasting neurological sequelae.
Beyond the individual clinical resolution, the incident has prompted a review by the local health authority of the prescribing guidelines for vitamin D supplementation in children, an inquiry that has highlighted the need for clearer dosage charts, mandatory electronic decision‑support alerts for high‑risk prescriptions, and reinforced training for clinicians on the pharmacodynamics of fat‑soluble vitamins, all of which aim to prevent recurrence of similar dosing errors that can have potentially life‑threatening consequences.
Moreover, the pharmacy involved has announced an internal audit of its dispensing procedures, acknowledging that reliance on manual verification without a second‑level check may have contributed to the oversight, and pledging to adopt electronic barcode scanning and automated dosage verification systems that have been shown to reduce medication errors in comparable healthcare settings.
From a broader perspective, the case underscores the paradox that treatments intended to support normal development can, when mishandled, generate clinical pictures that bewilder both families and professionals alike, thereby illustrating how the very mechanisms designed to safeguard paediatric health may, in the absence of robust systemic safeguards, become sources of preventable harm.
In reflecting on the experience, the family expressed a mixture of relief at the resolution of the feared tumour diagnosis and frustration at the preventable nature of the error, a sentiment that resonates with many patient advocacy groups urging healthcare systems to adopt a culture of safety that prioritises accurate dosing, clear communication, and rigorous verification at every step from prescription to administration.
Ultimately, while the child’s swift recovery serves as a testament to the effectiveness of prompt medical intervention once the error was identified, the incident remains a cautionary narrative about the importance of meticulous attention to detail in paediatric prescribing practices, the necessity for enhanced pharmacy safeguards, and the ongoing responsibility of healthcare institutions to close procedural gaps before they manifest as clinical crises that could otherwise be avoided.
Published: April 18, 2026